Lenalidomide May Overcome Rituximab Resistance in B-Cell Lymphomas

Share this content:
Combination lenalidomide and rituximab overcomes prior rituximab resistance in indolent B-cell and mantle cell lymphomas.
Combination lenalidomide and rituximab overcomes prior rituximab resistance in indolent B-cell and mantle cell lymphomas.

The combination of lenalidomide and rituximab overcomes prior rituximab resistance in patients with indolent B-cell and mantle cell lymphomas, a recent study published in the journal Clinical Cancer Research has shown.

For the single-center, phase II study, researchers sought to investigate whether the addition of lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, could improve clinical outcomes in patients with certain B-cell lymphomas who were previously resistant to rituximab treatment.

Researchers enrolled 50 patients with either indolent B-cell lymphoma or mantle cell lymphoma who were previously rituximab-resistant.

All patients received lenalidomide 10mg daily for 8 weeks, followed by rituximab 375mg/m2 weekly for 4 weeks. Patients continued to receive lenalidomide during and after rituximab.

RELATED: Disease Progression of Mantle Cell Lymphoma After Ibrutinib Associated with Poor Outcome

Results showed that for the 43 evaluable patients, the overall response rate after 8 weeks of lenalidomide was 30.2% and 62.8% 12 weeks after addition of rituximab to lenalidomide. For all 50 patients, the median progression-free survival was 22.2 months after a median follow-up of 39.2 months.

Researchers found that progression-free survival after receiving this drug combination was significantly longer than the progression-free survival for the standard regimen used to overcome rituximab resistance (22.2 vs. 9.13 months; P = 0.0004).

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters